RheumJC4 Part 2: Tapering Biologics--Why, How, and What If

May 21, 2015

In the second installment of a slide show based on an animated discussion by members of the rheumatology journal club (#rheumjc), partipants focus on the benefits, risks, and realities of tapering biologics in clinical practice.

Part 2 of our slide show summarizing the latest conversation of the Twitter-based rheumatology journal club #rheumjc looks into tapering of biologics for rheumatoid arthritis in actual practice.Three of the participating rheumatologists practice outside the United States, offering a noteworthy difference of perspective.The discussion in Part 1 focused on a randomized trial of biologic tapering published recently in BMJ. Here, participants focused on the clinical realities: Why to taper, whom to taper, when to start tapering, how to decide whether restarting the biologic is warranted, and what happens next.

x